Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies-Reference-Cited by-同舟云学术

Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies

Published:2011-11-18 Issue:4 Volume:31 Page:631-636
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Wong Anna K.,Kerkoutian Susan,Said Jonathan,Rashidi Hooman,Pullarkat Sheeja T.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-011-1895-y.pdf

Reference29 articles.

1. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916

2. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bill H et al (1994) Randomised double blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110

3. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al (1997) Treatment of rheumatoid arthritis with a recombinant human necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147

4. Salfeld J, Kaymakcalan Z, Tracey D, Roberts A, Kamen R (1998) Generation of fully human anti-TNF antibody D2E7[abstract]. Arthritis Rheum 41(Suppl 9):S57

5. Bare P, Joosten LA, den Broeder AA, van de Putte LB, Van Riel PL, van den Berg WB (2001) Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF alpha in patients with rheumatoid arthritis. Ann Rheum Dis 60:660–669

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Access and use of immunoglobulins in supportive cancer care: A thematic analysis of a systematic review data set;The Journal of Medicine Access;2024-01

2. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook;Expert Review of Clinical Immunology;2023-08-14

3. Current Medical and Surgical Treatment of Hidradenitis Suppurativa—A Comprehensive Review;Journal of Clinical Medicine;2022-12-06

4. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study;RMD Open;2022-12

5. Lymphoma developing in a patient with long-term antitumor necrosis factor therapy;Dermatology Practical & Conceptual;2022-07-28